ENGN, ENGNW · CIK 0001980845 · operating
Based in Montreal, Quebec, enGene Holdings Inc. operates as a clinical-stage biotechnology company focused on developing genetic medicines for oncology indications. The company's primary focus is bladder cancer, specifically non-muscle invasive bladder cancer (NMIBC). Its lead product candidate, detalimogene voraplasmid, is being evaluated as a monotherapy for NMIBC treatment and represents the company's most advanced development program.
The company's pipeline includes the LEGEND program, currently in Phase 2 development. As a clinical-stage entity, enGene does not generate revenue from approved products. The organization operates with a workforce of 81 full-time employees and maintains operations primarily from its Canadian headquarters. The company is incorporated at the federal level in Canada and trades on the Nasdaq exchange, providing access to U.S. capital markets.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $2.29 | $2.29 | +56.8% | |
| 2024 | $1.46 | $1.46 | -99.0% | |
| 2023 | $151.22 | $151.22 | — |